A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3652 in Healthy Young and Elderly Male and Female Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs ASP 3652 (Primary)
- Indications Interstitial cystitis; Prostatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma BV
Most Recent Events
- 17 Jul 2020 Results from 2 studies assessing safety, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ASP3652, published in the Advances in Therapy.
- 22 Sep 2014 New trial record